Engineering Morphogenetic Factors for Enhanced Genetic Reprogramming
Engineering Morphogenetic Factors for Enhanced Genetic Reprogramming
批准号:
8146777
负责人:
Charles A. Gersbach
金额:
$235.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-30 至 2016-06-30
关键词:
AddressAreaBiochemistryBiomedical ResearchCardiovascular DiseasesCell Differentiation processCell Fate ControlCell LineageCell TherapyCellsComplexDevelopmentDirected Molecular EvolutionEngineeringFrequenciesGene ExpressionGenesGeneticGenetic TranscriptionHealthHumanMammalian CellMethodsMolecular ProfilingMusculoskeletal DiseasesNerve DegenerationOutputPhenotypePropertyProteinsRegenerative MedicineScientistSourceTechnologyTimeTranscriptional RegulationTranslatingVariantWorkWound Healingabstractingcell behaviordirected evolutionenhancing factorimprovedinduced pluripotent stem cellinnovationinsightprotein functionpublic health relevancetranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant)
Abstract: Recent advances in the genetic reprogramming of mammalian cells are challenging the traditional concepts of cell differentiation and providing new avenues for regenerative medicine. These studies have shown that cellular transcription machinery can be manipulated to reprogram gene expression profiles and redirect cell behavior. Highlighted by recent progress in the development of induced pluripotent stem cells (iPSCs), the principles of genetic reprogramming are also generally applicable to controlling a wide variety of cellular phenotypes. In fact, many cell lineages are defined by a single master regulatory transcription factor, several of which are currently being used to control cell fate for gene- and cell-based therapies and other biotechnological applications. However, current methods for genetic reprogramming are limited by several inefficiencies, including a low frequency of reprogrammed cells, long times to achieve full reprogramming, and insufficient robustness of new cell phenotypes. To address these limitations, we propose to enhance the intrinsic properties of the reprogramming factors through directed molecular evolution. This represents a new conceptual direction in the area of genetic reprogramming and capitalizes on the recent progress in the area of directed evolution for enhancing protein function. Importantly, this approach is broadly applicable to improving the efficacy of any transcriptional regulation machinery and therefore will be beneficial to numerous applications and fields of biomedical research. The outputs of this work will include the discovery of transcription factor variants with enhanced reprogramming capabilities, insights into the biochemistry of morphogenetic transcription factors, and the development of new methods for controlling cell behavior. Additionally, this study will propel the field of directed evolution into the new areas of genetic reprogramming and regenerative medicine. This synergistic incorporation of technologies represents the innovation that will be necessary to translate the transformative advances of biomedical research into real benefits for human health.
Public Health Relevance: Scientists are investigating methods to use naturally occurring proteins to coordinate complex cell behaviors, including tissue repair. Although this approach shows tremendous promise, these natural proteins are often insufficient for effectively directing cell activity. This proposal outlines a new and unique technology for evolving engineered versions of these proteins that will be more effective in generating robust cell sources for a variety of applications, including the treatment of cardiovascular disease, neurodegenerative conditions, and musculoskeletal disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University Training Program in Biomolecular and Tissue Engineering
-
批准号:10652660
-
项目类别:
-
资助金额:$53.05万
-
财政年份:2022
-
负责人:Charles A. Gersbach
-
依托单位:
Epigenome Editing Technologies for Treating Diverse Disease
-
批准号:9810824
-
项目类别:
-
资助金额:$40.04万
-
财政年份:2019
-
负责人:Charles A. Gersbach
-
依托单位:
Epigenome Editing Technologies for Treating Diverse Disease
-
批准号:10214461
-
项目类别:
-
资助金额:$39.87万
-
财政年份:2019
-
负责人:Charles A. Gersbach
-
依托单位:
Epigenome Editing Technologies for Treating Diverse Disease
-
批准号:9973203
-
项目类别:
-
资助金额:$38.51万
-
财政年份:2019
-
负责人:Charles A. Gersbach
-
依托单位:
Epigenome Editing Technologies for Treating Diverse Disease
-
批准号:10438803
-
项目类别:
-
资助金额:$39.85万
-
财政年份:2019
-
负责人:Charles A. Gersbach
-
依托单位:
CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy
-
批准号:9888311
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2016
-
负责人:Charles A. Gersbach
-
依托单位:
In Vivo Epigenome Editing with CRISPR-Based Histone Acetyltransferase Transgenic Mice
-
批准号:9132500
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2016
-
负责人:Charles A. Gersbach
-
依托单位:
In Vivo Epigenome Editing with CRISPR-Based Histone Acetyltransferase Transgenic
-
批准号:9895699
-
项目类别:
-
资助金额:$38.06万
-
财政年份:2016
-
负责人:Charles A. Gersbach
-
依托单位:
CRISPR/Cas9-Based Gene Editing for the Correction of Duchenne Muscular Dystrophy
-
批准号:9237199
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2016
-
负责人:Charles A. Gersbach
-
依托单位:
Scaffold-Mediated Gene Delivery for Engineering of Osteochondral Tissues
-
批准号:9069429
-
项目类别:
-
资助金额:$19.96万
-
财政年份:2015
-
负责人:Charles A. Gersbach
-
依托单位:
Scaffold-Mediated Gene Delivery for Engineering of Osteochondral Tissues
-
批准号:8815847
-
项目类别:
-
资助金额:$16.67万
-
财政年份:2015
-
负责人:Charles A. Gersbach
-
依托单位:
Genome Editing of Stem Cells for Analysis of Osteoarthritis Causal Variants
-
批准号:8663739
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2014
-
负责人:Charles A. Gersbach
-
依托单位:
Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven Scaffolds
-
批准号:8100077
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2011
-
负责人:Charles A. Gersbach
-
依托单位:
Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven Scaffolds
-
批准号:8452615
-
项目类别:
-
资助金额:$7.22万
-
财政年份:2011
-
负责人:Charles A. Gersbach
-
依托单位:
Spatially Controlled Gene Delivery of Morphogenetic Factors from Woven Scaffolds
-
批准号:8249080
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2011
-
负责人:Charles A. Gersbach
-
依托单位:
Regulating Sensitivity to Cancer Therapy with Engineered Transcription Factors
-
批准号:7220428
-
项目类别:
-
资助金额:$4.68万
-
财政年份:2007
-
负责人:Charles A. Gersbach
-
依托单位:
Regulating Sensitivity to Cancer Therapy with Engineered Transcription Factors
-
批准号:7590466
-
项目类别:
-
资助金额:$1.67万
-
财政年份:2007
-
负责人:Charles A. Gersbach
-
依托单位:
Regulating Sensitivity to Cancer Therapy with Engineered Transcription Factors
-
批准号:7429645
-
项目类别:
-
资助金额:$4.96万
-
财政年份:2007
-
负责人:Charles A. Gersbach
-
依托单位:
University Training Program in Biomolecular and Tissue Engineering
-
批准号:9069933
-
项目类别:
-
资助金额:$37.06万
-
财政年份:1994
-
负责人:Charles A. Gersbach
-
依托单位:
University Training Program in Biomolecular and Tissue Engineering
-
批准号:8895340
-
项目类别:
-
资助金额:$41.05万
-
财政年份:1994
-
负责人:Charles A. Gersbach
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: